Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations, expanding the addressable patient population by offering one solution for many mutations. Our mission: defeat cancer resistance and provide people living with cancer the opportunity to experience longer, healthier and more active lives. We are advancing two potent, brain-penetrant clinical-stage programs: BDTX-1535, a fourth-generation EGFR inhibitor targeting non-small cell lung cancer (NSCLC) and glioblastoma (GBM) and BDTX-4933, a RAF inhibitor targeting KRAS, NRAS and BRAF alterations in NSCLC and other solid tumors.

Biotechnology Value Fund

BVF Partners

City Hill Ventures

Wellington Management

Logos Capital

New Enterprise Associates

Invus

Nextech Invest

Roche Venture Fund

Versant Ventures

Perceptive Advisors

Black Diamond Therapeutics

Endpoints' recent coverage of a new survey on the state of the continuously evolving #NSCLC therapeutic landscape reflects progress for the field but still huge unmet need https://lnkd.in/e7AGnJqn. Fewer than one in five oncologists rated the current treatment options as excellent, and the majority are seeking additional treatment options for advanced forms of #cancer, as well as tools to assess biomarkers and other predictive methods that inform treatment efficacy. To learn more about BDTX's unique approach to expand the scope of NSCLC therapies and about its investigational MasterKey drug candidates, visit https://lnkd.in/eWvbfvKc

We expect an exciting year ahead as we continue advancing our clinical programs with the goal of enabling patients to live healthier, longer lives. We anticipate several important BDTX-1535 milestones in 2024, including Phase 2 results for the treatment of #NSCLC, as well as medical meeting presentations of Phase 1 data sets for the treatment of #GBM. We also expect BDTX-4933 Phase 1 results for the treatment of KRASm NSCLC.

Read more: https://lnkd.in/eMiiNsSg

#LungCancer #Glioblastoma

Today we announced topline results from our Phase 1 dose escalation trial in recurrent #GBM, where historical PFS ranges from 2-4 months. BDTX-1535 demonstrated promising clinical activity and more than 1/3 of patients remained on therapy greater than 4 months. These results in heavily pretreated patients are an important first step in understanding the potential of BDTX-1535 to benefit newly-diagnosed GBM patients. We anticipate results from a "window of opportunity" clinical trial of BDTX-1535 in second-line patients with high-grade glioma in 2Q 2024.

Read more: https://lnkd.in/eU7hFh8F

This weekend, Black Diamond will be in the Windy City, joining other pioneers in #oncology at the #IASLC North America Conference on Lung Cancer for robust knowledge exchange and immersion in the latest research as we further advance our pipeline of MasterKey inhibitors for #EGFR, #KRAS and #BRAF driven #NSCLC. 

To learn more about our pipeline, visit: https://lnkd.in/ek2kyjwV

#NACLC23

Lung cancer is the second most common form of cancer in both men and women in the US, according to the American Cancer Society, and November is #LungCancerAwareness Month. The more than 200,000 diagnoses each year inspire, encourage, and empower us every day to relentlessly pursue our mission of developing potentially life changing treatments for patients living with mutated forms of non small cell lung cancer: BDTX-1535 and BDTX-4933. #NSCLC #EGFR #KRAS

To read more about Lung Cancer Awareness Month, visit American Lung Association: https://lnkd.in/dnXYGtR

And to learn more about Black Diamond’s unique approach to targeting families of oncogenic mutations, click here: https://lnkd.in/em4gMAWM

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
average inventory
average payables		284K -	1.19M 319.01%	2.25M 89.16%	3.32M 47.60%	2.99M 9.95%	2.10M 29.80%
average receivables
book value per share	-0.93 -	-1.11 20.10%	-1.56 40.19%	-3.59 130.04%	-6.74 87.53%	-9.22 36.88%	0.00 100.03%
capex per share	-0.01 -	-0.01 49.09%	-0.00 88.19%	-0.00 570.63%	-0.07 1,635.38%	-0.01 92.94%
capex to depreciation	-3.21 -	-1.73 46.16%	-0.45 74.13%	-2.73 511.17%	-13.22 384.09%	-0.38 97.14%
capex to operating cash flow	0.03 -	0.01 72.55%	0.00 90.53%	0.00 219.95%	0.03 893.71%	0.00 91.66%
capex to revenue
cash per share	1.09 -	3.70 238.23%	4.74 27.98%	9.57 102.03%	5.80 39.45%	3.38 41.68%	0.00 99.96%
days of inventory on hand
days payables outstanding
days sales outstanding
debt to assets				0.03 -	0.11 333.37%	0.18 56.73%	0.14 22.31%
debt to equity				-0.07 -	-0.12 57.87%	-0.08 28.03%	0.19 326.24%
dividend yield
earnings yield	-0.02 -	-0.02 0.10%	-0.03 96.92%	-0.06 94.43%	-0.64 928.81%	-1.29 102.38%	-0.00 99.95%
enterprise value	276.21M -	499.13M 80.70%	1.13B 127.16%	1.03B 9.26%	155.55M 84.88%	59.21M 61.93%	123.48B 208,439.65%
enterprise value over ebitda	-67.35 -	-56.26 16.47%	-49.43 12.14%	-15.30 69.05%	-1.24 91.90%	-0.62 49.71%	-1.43K 229,182.67%
ev to operating cash flow	-117.49 -	-59.04 49.75%	-45.95 22.17%	-19.73 57.07%	-1.55 92.13%	-0.70 55.19%	-1.85K 265,843.77%
ev to sales
free cash flow per share	-0.34 -	-0.61 81.21%	-0.76 23.75%	-1.59 109.99%	-2.84 78.87%	-2.35 17.41%	-0.00 99.94%
free cash flow yield	-0.01 -	-0.02 81.21%	-0.02 23.75%	-0.05 158.68%	-0.53 975.60%	-1.30 144.57%	-0.00 99.96%
graham net net	-0.95 -	-1.13 18.83%	-1.67 48.58%	8.91 632.51%	-7.78 187.38%	2.26 129.09%	0.00 99.99%
graham number	3.65 -	4.01 9.64%	6.66 66.15%	12.68 90.55%	22.72 79.12%	21.97 3.28%	0.01 99.95%
income quality	0.51 -	0.95 85.29%	0.70 26.07%	0.78 10.80%	0.80 2.84%	0.93 17.04%	0.81 13.28%
intangibles to total assets	0 -	0	0	0	0	0	0
interest coverage	-63.37 -			-69.57K -		23.75 -
interest debt per share	0.01 -			0.27 -	0.79 196.03%	0.67 15.18%	0.00 99.92%
inventory turnover
invested capital				-0.07 -	-0.12 57.87%	-0.08 28.03%	0.19 326.24%
market cap	284.09M -	550.79M 93.88%	1.29B 133.94%	1.05B 18.15%	192.89M 81.71%	65.39M 66.10%	123.51B 188,797.41%
net current asset value	-6.78M -	-15.68M 131.26%	-54.60M 248.12%	297.64M 645.14%	-281.72M 194.65%	87.15M 130.93%	92.20M 5.80%
net debt to ebitda	1.92 -	5.82 203.11%	6.74 15.79%	0.38 94.30%	0.30 22.70%	0.06 78.15%	0.39 506.02%
net income per share	-0.64 -	-0.64 0.10%	-1.26 96.92%	-1.99 57.84%	-3.40 71.09%	-2.33 31.66%	-0.00 99.92%
operating cash flow per share	-0.33 -	-0.61 85.48%	-0.76 24.76%	-1.58 109.60%	-2.77 74.64%	-2.34 15.36%	-0.00 99.94%
payables turnover
receivables turnover
research and ddevelopement to revenue
return on tangible assets	-0.57 -	-0.17 69.96%	-0.26 50.83%	-0.20 23.58%	-0.50 150.44%	-0.54 8.74%	-0.52 3.88%
revenue per share
roe	0.69 -	0.57 16.65%	0.81 40.47%	0.55 31.39%	0.51 8.77%	0.25 50.07%	-0.71 379.91%
roic	0.62 -	0.57 8.61%	0.20 64.31%	0.67 229.83%	0.67 0.96%	0.32 52.46%	-0.54 269.52%
sales general and administrative to revenue
shareholders equity per share	-0.93 -	-1.11 20.10%	-1.56 40.19%	-3.59 130.04%	-6.74 87.53%	-9.22 36.88%	0.00 100.03%
stock based compensation to revenue
tangible asset value	-6.67M -	-15.54M 132.84%	-50.97M 227.95%	307.76M 703.80%	-243.82M 179.22%	115.69M 147.45%	116.74M 0.90%
tangible book value per share	-0.93 -	-1.11 20.10%	-1.56 40.19%	9.35 698.84%	-6.74 172.04%	3.18 147.27%	0.00 99.92%
working capital	5.68M -	49.11M 763.99%	149.80M 205.04%	305.34M 103.83%	186.14M 39.04%	112.44M 39.59%	114.39M 1.73%

NASDAQ:BDTX

Black Diamond Therapeutics

Last Close

5.44

16/05 17:28

Market Cap

149.74M

Beta: 1.88

Volume Today

1.28M

Avg: 83.37K

PE Ratio

−2.55

PFCF: −2.76